SCA
KPTI icon

Spearhead Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Spearhead Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,297
Closed -$222K – 214
2021
Q4 		$222K Buy
2,297
+53
+2% +$5.28K 0.03% 166
2021
Q3 		$196K Sell
2,244
-25
-1% -$2.6K 0.03% 183
2021
Q2 		$351K Buy
2,269
+467
+26% +$67.8K 0.05% 165
2021
Q1 		$284K Buy
+1,802
New +$380K 0.04% 170

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ITP
Iron Triangle Partners Cos Cob, Connecticut $875M AUM 49.85% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Spearhead Capital Advisors's KPTI Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2022, closing a stake of 2,297 shares — an estimated $222K sold.

Spearhead Capital Advisors first reported a position in KPTI in Q1 2021 and held it in 4 quarters. The position peaked at $351K in Q2 2021. 139 funds tracked by Wall St. Rank hold KPTI as of Q1 2022.

  • Spearhead Capital Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 2,297 Karyopharm Therapeutics shares in Q1 2022, an estimated $222K.
  • Spearhead Capital Advisors first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 4 quarters.
  • Spearhead Capital Advisors's Karyopharm Therapeutics position peaked at $351K in Q2 2021.
  • 139 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.